Solebury Trout Talks: Interview with Dale Chappell, Humanigen - Part of the Nametag Series
- Founder, Black Horse Capital Advisors
- Decades of biotechnology investment experience
- HHMI Fellow, National Cancer Institute, Rosenberg Lab
- Multiple publications in T-cell therapy, GM-CSF and immunology pathways
These podcasts are intended to provide biographical or other general information about the executive being interviewed or the company that employs the executive, and are not intended to serve as a complete analysis of all material facts regarding any company, industry, or security. The views expressed here are those of the executives being interviewed, or the companies that employ them, and not those of Solebury Trout or its affiliates. Solebury Trout does not make any representation or warranty, express or implied, as to the accuracy or completeness of the statements or any information contained in these podcasts. References to any specific products, services, strategies, research, therapies, or entities in these podcasts do not constitute endorsements or recommendations by Solebury Trout.
The information in these podcasts may contain projections or other forward‐looking statements regarding future events, targets, forecasts or expectations regarding the strategies described therein, and is only current as of the date indicated. There is no assurance that such events or targets will be achieved and you should not place undue reliance on such statements, as actual results could vary substantially due to subsequent market events or other developments. Past performance is not a guarantee of future performance. The information is as of the date presented and neither the speaker nor Solebury Trout undertakes to advise you of any changes or provide any updates to such information.
This website and the podcasts are for general information purposes only and are not an offer or a solicitation to buy or sell securities, and do not constitute investment advice.